首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Protective Effects of Hong Shan Capsule against Lethal Total-Body Irradiation-Induced Damage in Wistar Rats
【2h】

Protective Effects of Hong Shan Capsule against Lethal Total-Body Irradiation-Induced Damage in Wistar Rats

机译:红山胶囊对Wistar大鼠全辐射辐照致死性损伤的保护作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hong Shan Capsule (HSC), a crude drug of 11 medicinal herbs, was used in clinical practice for the treatment of radiation injuries in China. In this study, we investigated its protection in rats against acute lethal total-body irradiation (TBI). Pre-administration of HSC reduced the radiation sickness characteristics, while increasing the 30-day survival of the irradiated rats. Administration of HSC also reduced the radiation sickness characteristics and increased the 30-day survival of mice after exposure to lethal TBI. Ultrastructural observation illustrated that the pretreatment of rats with HSC significantly attenuated the TBI-induced morphological changes in the different organs of irradiated rats. Gene expression profiles revealed the dramatic effect of HSC on alterations of gene expression caused by lethal TBI. Pretreatment with HSC prevented differential expression of 66% (1398 genes) of 2126 genes differentially expressed in response to TBI. Pathway enrichment analysis indicated that these genes were mainly involved in a total of 32 pathways, such as pathways in cancer and the mitogen-activated protein kinase (MAPK) signaling pathway. Our analysis indicated that the pretreatment of rats with HSC modulated these pathways induced by lethal TBI, such as multiple MAPK pathways, suggesting that pretreatment with HSC might provide protective effects on lethal TBI mainly or partially through the modulation of these pathways. Our data suggest that HSC has the potential to be used as an effective therapeutic or radio-protective agent to minimize irradiation damage.
机译:洪山胶囊(HSC)是由11种草药制成的粗制药物,在中国的临床实践中用于治疗放射损伤。在这项研究中,我们调查了其在大鼠中对急性致死性全身照射(TBI)的保护作用。 HSC的预先给药降低了放射病的特征,同时增加了被辐照大鼠的30天生存期。 HSC的使用还降低了放射病的特征,并增加了暴露于致死性TBI后小鼠的30天存活率。超微结构观察表明,HSC大鼠的预处理显着减弱了TBI诱导的辐照大鼠不同器官中的形态变化。基因表达谱揭示了HSC对由致死性TBI引起的基因表达改变的巨大影响。用HSC预处理可防止在响应TBI时差异表达的2126个基因中有66%(1398个基因)的差异表达。途径富集分析表明,这些基因主要参与总共32条途径,例如癌症途径和有丝分裂原活化蛋白激酶(MAPK)信号传导途径。我们的分析表明,用HSC预处理的大鼠调节了由致死性TBI诱导的这些途径,例如多个MAPK途径,这表明用HSC预处理可能通过这些途径的调节而部分或部分对致死性TBI提供保护作用。我们的数据表明,HSC有潜力用作有效的治疗或放射防护剂,以最大程度地减少辐射损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号